"Detox" nearly sank the deal."排毒"两个字，差点毁掉这笔交易。

Why a capable factory did not see it coming一家有真本事的工厂，为什么完全没料到这一点？

The factory in this case had what most buyers would call real capability: a working facility, basic QA records, a signed sample-order relationship already in motion with a small U.S. distributor. The gap had nothing to do with production. It was that the label and marketing copy had been written for a Chinese-market audience and translated for fluency, by people with no reason to know that U.S. law treats a beverage's advertising claims as a legal classification question rather than a stylistic one. A phrase that reads as ordinary, even understated, tea marketing in one regulatory system reads as an unapproved drug claim in another, and nothing about the words themselves signals which system applies.本案里的这家工厂，按大多数买家的标准，是有真实能力的：有实际运转的厂房，有基础的质量记录，也已经和一家美国小型经销商建立了签约中的样品订单关系。缺口和生产完全无关。问题在于，标签和营销文案是面向中国市场受众写的，翻译时追求的是流畅，而写文案和译文案的人都没有理由知道，美国法律把一款饮品的广告宣称当作一个法律归类问题来处理，而不是一个文风问题。同一句话，在一个监管体系里读起来平平无奇，甚至偏保守，在另一个体系里就成了未经批准的药品宣称，文字本身完全不会提示你此刻适用的是哪一套体系。

The distributor's own compliance reviewer caught it before a purchase order was issued, sending back a one-line message to the effect that half the claims as written would turn the product into a drug. That is a good outcome by the standard of what could have happened instead. A shipment that moved further downstream with the same language on the label carries meaningfully higher exposure, for the distributor as much as the supplier. That's because the FTC has its own, separate jurisdiction over advertising claims — its standard for a health-related efficacy claim is generally competent and reliable scientific evidence, which testimonials and traditional-use claims don't satisfy — and that standard applies to marketing copy on top of whatever FDA's labeling rules say about the label itself.经销商自己的合规审查人员，在采购订单下达之前就发现了这个问题，回了一句话，大意是：文案里差不多一半的宣称，如果照原样使用，会把产品变成一种药品。相比可能发生的其他情况，这已经算是一个不错的结果。如果一批货带着同样的标签文案继续往下游走，无论对经销商还是对供应商，风险都会明显更高。这是因为 FTC 对广告宣称还有一套独立的管辖权——其对健康功效类宣称的标准通常是"充分可靠的科学证据"，用户证言和传统用法类宣称达不到这个门槛——这套标准适用于营销文案，而不只是FDA标签规则所管的标签本身。

Naming every claim before deciding what to do about it先把每一条宣称都点清楚，再决定怎么处理

The first move was not to start rewriting copy. It was to build a line-by-line issue log covering every claim on the label, the packaging mockup, and the website and marketing materials, each entry logged with its exact wording, its likely classification (structure/function, disease claim, or ambiguous), and the specific rule it implicated. This is an organizing and evidence-mapping exercise, not a legal opinion, and it was treated that way throughout: the log tells a specialist where to look and why, it does not tell the supplier what is legal.第一步不是动手改文案，而是建立一份逐条梳理的问题清单，覆盖标签、包装样稿以及网站和营销材料上的每一条宣称——每一条都记录下准确措辞、可能的分类判定（结构/功能宣称、疾病宣称，或者模糊地带），以及涉及的具体规则。这是一项梳理和证据映射的工作，不是法律意见，而且从头到尾都是按这个定位来处理的：这份清单告诉专业顾问该看哪里、为什么要看，它不告诉供应商什么是合法的。

Alongside the claims themselves, the label had gaps that were unrelated to the disease-claim question but would have surfaced sooner or later on their own: no correctly formatted Nutrition Facts or Supplement Facts panel depending on how the product would ultimately be positioned, no manufacturer/packer/distributor name and address per 21 CFR 101.5, and no documented allergen review under FALCPA — the Food Allergen Labeling and Consumer Protection Act, which requires a label to call out any of the nine major allergens it contains — even though a plain tea and botanical blend is unlikely to contain any of them. None of these were dramatic on their own. Together, logged and dated, they gave the engagement a complete picture instead of a single fire to put out.除了宣称本身，标签上还存在一些和疾病宣称问题无关、但迟早会自己暴露出来的缺口：根据产品最终的定位方式，营养成分标示或补充剂成分标示的格式不正确；没有按 21 CFR 101.5 的要求标注生产商/包装商/经销商的名称和地址；也没有按 FALCPA（《食品过敏原标示与消费者保护法》，要求标签上标明产品含有的九大主要申报过敏原）的要求做过书面的过敏原审查，尽管一款纯茶和植物混合产品含有这些过敏原的可能性本来就不高。这些单独看都算不上大事。但被逐一记录、注明日期之后，整个项目拿到的是一幅完整的图景，而不是只顾着扑灭一处火。

The issue log also did something more specific: it explained, in the supplier's own terms, why the buyer's procurement team had escalated this rather than simply asking for a revision. The distributor's supplier questionnaire required a signed label-compliance attestation before a purchase order. The claims problem was not the distributor being cautious for its own sake, it was the distributor's own paperwork gate doing exactly what it was designed to do.这份问题清单还做了一件更具体的事：它用供应商自己能理解的方式，解释了为什么买方的采购团队会选择升级审查，而不是简单地要求改一改文案。经销商的供应商问卷要求在下采购订单前，提交一份签字的标签合规确认书——宣称问题不是经销商在自我保护式地谨慎行事，而是经销商自己的文件关卡，正在按设计意图发挥作用。

A specialist decides, not Easterlies做判定的是专业顾问，不是Easterlies

Claims classification and disclaimer language are not something Easterlies performs or signs off on. The issue log was handed to a qualified food-labeling consultant, a category of firm distinct from a law firm, focused on label mechanics and claims review, who used it to shorten their own discovery time rather than starting from a blank label. Where individual claims carried disease-claim exposure serious enough to warrant a legal read, that referral went to regulatory counsel, on the specialist's judgment of risk, not Easterlies'.宣称分类和免责声明文字，从来不是Easterlies执行或签署的内容。这份问题清单被交给了一位合格的食品标签顾问——这是一类区别于律师事务所的专业机构，专注于标签细节和宣称审查——对方拿着这份清单，省去了从零开始摸底的时间，而不是面对一张空白标签重新开始。对于风险严重到需要法律判断的个别宣称，转介交给了监管律师，这是基于顾问自己对风险的判断，而不是Easterlies的判断。

The specialist determined the food-versus-supplement positioning, rewrote the claim language, and where the supplement pathway applied, added the disclaimer required under DSHEA — the Dietary Supplement Health and Education Act, which requires any structure/function claim to carry a standard line stating the FDA hasn't evaluated it — and filed the corresponding FDA notification. Easterlies scheduled the engagement, briefed the specialist with the issue log, and once cleared copy came back, helped assemble the distributor's compliance-attestation paperwork referencing the specialist's own sign-off.这位顾问最终确定了食品还是膳食补充剂的定位，重写了宣称文字，在适用膳食补充剂路径的情况下，加上了 DSHEA（《膳食补充剂健康与教育法》，规定结构/功能宣称必须搭配一句"本品未经 FDA 评估"的标准免责声明）要求的免责声明，并提交了相应的FDA备案通知。Easterlies安排了这次对接、用问题清单为顾问做了前期简报，在收到通过审核的文案后，协助整理了引用该顾问签署意见的经销商合规确认文件。

What came out the other side was a revised label and marketing package that could go back to the distributor's compliance desk as a complete resubmission, correct claim language, correct Nutrition Facts formatting, the required disclaimer in place. That is a meaningfully different outcome than "the distributor placed an order," and it was never described as one. FDA does not pre-clear label claims, so no one can promise the agency will never act on a given label; what changed is that the claims on this one were reviewed by someone qualified to review them, and the paperwork trail now shows that. The product did not change. The words describing it, and who stood behind those words, did.最终拿到的，是一份可以作为完整重新提交材料、送回经销商合规审查部门的修订版标签和营销文案——宣称措辞准确，营养成分标示格式正确，所需的免责声明也已到位。这和"经销商下了订单"是两件完全不同的事，而且我们从未这样描述过。FDA不会预先批准标签宣称，所以没有人能保证监管部门未来绝不会对某份标签采取行动；真正改变的是，这批宣称已经由具备资质的人审查过，而且这一过程现在有据可查。产品本身没有变，变的是描述它的文字，以及为这些文字背书的是谁。